Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 187Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 66Neoplasms 62Ovarian Neoplasms 59Glioblastoma 40Carcinoma, Hepatocellular 36Neoplasm Metastasis 32Colonic Neoplasms 27Carcinoma, Renal Cell 24Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 21Rectal Neoplasms 17Pancreatic Neoplasms 17Lung Neoplasms 17Stomach Neoplasms 15Liver Neoplasms 15Brain Neoplasms 14Non-Squamous Non-Small Cell Lung Cancer 13Endometrial Neoplasms 11Recurrence 10Glioma 10Carcinoma, Ovarian Epithelial 10Triple Negative Breast Neoplasms 9Melanoma 9Gastrointestinal Neoplasms 9Advanced Solid Tumors 9Solid Cancers 7Peritoneal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

Folfox protocol 2pembrolizumab 1IFL protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Unresectable Metastatic Colorectal Cancer × Bevacizumab × Clear all
NCT05068206 2021-10-20

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
120 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡